Leading the Way in Life Science Technologies

GEN Exclusives

More »

October 15, Vol. 29, No. 18

  • Feature Articles

    • High-Content Screening Surges Ahead
    • Vicki Glaser
    • High-content screening (HCS) and the technology to do it faster, on more compounds in a shorter period of time, and to generate quantitative, multiparametric data took center stage at CHI’s “High Content East” meeting held in Boston last month Presenters ... more »
    • Use of Microarrays Increasing Rapidly
    • Sophia Fox
    • A team from the Technical University of Denmark and the Copenhagen University Hospital recently published research results obtained with a microfluidic device known as a Multi-Stringency Array Washer (MSAW) According to the researchers, the MSAW facilitates probe optimization and, therefore, ... more »
    • qPCR Faces Growing Pains Head-On
    • Kathy Liszewski
    • Quantitative PCR (qPCR) technologies have exploded in the last decade Commonly used for both diagnostics and basic research, new and exciting advances are being made in such areas as biomarker discovery and treatment monitoring This rapid growth has also come ... more »
    • Novel Tools Streamline Purification Process
    • K. John Morrow Jr.
    • Participants at a recent downstream processing meeting sponsored by Sartorius Stedim Biotech considered a host of new technologies to speed and streamline protein purification, including membrane chromatography, nanofiltration, ultraviolet irradiation for viral inactivation, and ultracentrifugation concentration technology... more »
    • GEN's Cryptogram Challenge Solved
    • Two scientists from Canada have figured out the answer to the Genetic Engineering & Biotechnology News Cryptogram Challenge Adrienne Halupa, PhD, serves as project manager/research associate in the department of chemistry at the University of Toronto Stephen Ross works as ... more »
  • Columns

    • DTC Genomics & Leading-Edge Ethics
    • Chris MacDonald, Ph.D.
    • Direct-to-consumer (DTC) personal genomics services such as those currently marketed by 23andMe, Navigenics, and deCode, among others, occupy a small place in today’s biotech industry, but an enormously important position on the trajectory of the industry This importance results not ... more »
    • Update on Evolving Regulatory Guidance
    • Bruce Mackler
    • The FDA’s position on a myriad of issues is constantly evolving Companies need to be aware of these pending and implemented changes and adjust their practices accordingly This month’s column will focus on ghost writing of medical journal articles, personnel ... more »
    • Merrion Strives to Turn IV Drugs into Tablets
    • Carol Potera
    • The drugs in the pipeline at Merrion Pharmaceuticals are not new chemical entities poised to become blockbuster drugs Instead, the company specializes in designing oral formulations for existing drugs that must be given intravenously or by injection Not only do ... more »
    • Firms Seek to Prove Cancer Stem Cell Hypothesis
    • Keith Markey
    • The pharmaceutical and biotech industries have begun to develop targeted inhibitors of pathways that contribute to tumorigenesis and metastasis These new medicines offer the promise of treating many types of cancer with greater efficacy and fewer unwanted side effects than ... more »
    • Cells That Get No Respect
    • Plant cell culture has not received the attention it deserves from biopharmaceutical companies, but that may change as research-level developments reach the corporate level One reason, said Karen McDonald, PhD, professor of chemical engineering and material science at the University ... more »